HEPARENTM is a sterile solution. Each ml contains 1,000 or 5,000 units Heparin Sodium, derived from intestinal Mucosa for use as an anticoagulant in water for injection and not more than 1% benzyl alcohol as preservative.
The potency is determined by biological assay, using a reference standard based upon units of Heparin activity per milligram.
- For anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extensions.
- For prophylaxis and treatment of pulmonary embolism.
- In atrial fibrillation with embolization.
- For diagnosis and treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation).
- For prevention of clotting in arterial and cardiac surgery.
- For prevention of cerebral thrombosis in evolving stroke.
- As an adjunct in treatment of coronary occlusion with acute myocardial infaraction.
- For prophlaxis and treatment of peripheral arterial embolism.
- Heparin may also be employed as an anticoagulant in:
- Blood transfusions
- Extracorporeal circulation
- Dialysis procedures
- Blood samples for laboratory purposes
Heparin Sodium should not be used in patients:
- With severe thrombocytopenia
- In whom suitable blood - coagulative tests - e.g., the whole blood clotting time, partial thromboplastin time etc, cannot be performed at appropriate intervals (those contraindication refers to full dose Heparin).
- There is usually no need to monitor coagulation parameters in patients receiving low dose Heparin.
Heparin is not intended for intra muscular use.
- Hypersensitivity: Patients with documented hypersensitivity to Heparin should be given the drug only in clearly life-threatening situations.
- Haemorrhage: Heparin Sodium should be used with extreme caution in diseased states in which there is increased danger of haemorrhage. Some of the conditions in which increased danger of haemorrhage exists are:
- Cardiovascular: Subacute bacterial endocarditis, arterial sclerosis, increased capillary permeability, during an immediately following major surgery, especially involving brain, spinal cord or eye.
- Haematologic: Conditions associated with increased bleeding tendencies, such as haemophilia, thrombocytopenia and some vascular purpuras.
- Gastro-Intestinal: Ulcreative lesions and continuous tube drainage of the stomach or small intestine.
- Other: Menstruation liver disease with imparied hemostasis.
Heparin should be given with caution to patients already receiving drugs that interfere with platelet aggregation such as acetylsalicylic acid and other drugs, which may increase the risk of haemorrhage such as Dextran, dipyridamole, streptokinase and enokinase.